MedTrace Logo

Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder)

NCT01536210 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2019-02-25

No results posted yet for this study

Summary

This study will evaluate clinical efficacy and safety of treatment with YY-162 in children with ADHD.

Conditions

  • Mental Disorders

Interventions

DRUG

YY-162

YY-162(Ginkgo extract 30mg + Ginseng extract 50mg) 1T/Three times a day(Tid) for 8 weeks, PO medication

DRUG

Placebo

Placebo 1T/ Three times a day (tid) for 8 weeks, PO medication

Sponsors & Collaborators

  • Yuyu Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • SooChurl Cho, MD, PhD · Seoul National University Hospital

  • HyunJu Hong, MD, PhD · Hallym University Hospital

  • EunJin Park, MD · Inje University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2012-08-31
Completion
2012-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01536210 on ClinicalTrials.gov